Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when DNTH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsDianthus raises $673.5M in public offering, selling 8.5M shares at $81 with full overallotment
Filed March 12, 2026 · Period ending March 10, 2026 · ~1 min read
Key Changes
-
high
Company completed public offering of 7.3M shares at $81/share plus 402K pre-funded warrants, raising approximately $673.5M net of fees after underwriters exercised full 1.16M share overallotment option.
Item 1.01, 8.01 verify on EDGAR → -
high
Offering represents approximately 8.5M shares total (including warrants), creating significant dilution for existing shareholders but substantially strengthening balance sheet with immediate capital infusion.
Item 1.01 verify on EDGAR → -
medium
Strong institutional demand evidenced by underwriters exercising full overallotment option on March 11, one day after pricing, suggesting positive market reception at $81 price point.
Item 1.01 verify on EDGAR → -
medium
Pre-funded warrants exercisable immediately at $0.001/share with ownership caps at 4.99%, 9.99%, or 19.99% to accommodate institutional investors with position limits; economically equivalent to common stock.
Item 1.01 verify on EDGAR → -
medium
Offering closed March 12, 2026; filing does not specify intended use of proceeds, which investors should monitor in upcoming quarterly reports or investor communications.
Item 1.01 verify on EDGAR →
Summary
Dianthus Therapeutics completed a substantial $673.5 million public offering, selling 7.3 million common shares at $81 per share alongside 402,468 pre-funded warrants priced at $80.999. The underwriters—led by Jefferies, TD Securities, Evercore, Stifel, and Guggenheim—exercised their full overallotment option for an additional 1.16 million shares within 24 hours of pricing, signaling robust institutional appetite. The total issuance of approximately 8.5 million shares represents meaningful dilution but provides the biotech company with significant capital runway.
Retail investors should note that while the filing confirms the capital raise mechanics, it does not disclose how management intends to deploy these proceeds—whether for clinical trials, manufacturing scale-up, acquisitions, or general corporate purposes. The strong demand and quick overallotment exercise suggest institutional confidence in the company's prospects at current valuation levels. Watch for management commentary in the next earnings call or investor presentation regarding capital allocation priorities and updated cash runway guidance, as this will determine whether the dilution proves value-accretive for existing shareholders.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On March 10, 2026, Dianthus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 7,313,582 shares of the Company’s common stock at a public offering price of $81.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 402,468 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a public offering price of $80.999 per share
The company entered into an underwriting agreement to sell 7.3 million shares at $81 per share and pre-funded warrants for 402,468 shares at $80.999 per share. This is a significant equity financing transaction that will dilute existing shareholders but provides substantial capital for operations.
Added in current filing · verify on EDGAR →
In addition, the Company has granted the Underwriters an option (the “Option”) for a period of 30 days to purchase up to an additional 1,157,407 shares of its common stock at the public offering price, less the underwriting discounts and commissions, which the Underwriters exercised in full on March 11, 2026.
The underwriters exercised their full overallotment option to purchase an additional 1.16 million shares. This indicates strong demand for the offering and increases total dilution but also increases capital raised.
Added in current filing · verify on EDGAR →
The net proceeds from the Offering, including proceeds from the exercise in full of the Option by the Underwriters, are expected to be approximately $673.5 million, after deducting the Underwriters’ discounts and commissions and estimated offering expenses.
The company expects to receive approximately $673.5 million in net proceeds after underwriting fees and expenses. This substantial cash infusion will strengthen the balance sheet and fund operations, though the 8-K does not specify intended use of proceeds.
Added in current filing · verify on EDGAR →
The Pre-Funded Warrants will be exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99%, 9.99%, or 19.99%, as applicable, of the number of shares of common stock outstanding immediately after giving effect to such exercise.
The pre-funded warrants are immediately exercisable at $0.001 per share but include ownership caps to prevent any single holder from exceeding specified ownership thresholds. These warrants are economically equivalent to common stock and will likely be exercised promptly.
Added in current filing · verify on EDGAR →
The Offering is expected to close on March 12, 2026.
The offering is scheduled to close on March 12, 2026, at which point the company will receive the proceeds and the new shares will be issued. This is imminent as of the filing date.
Event · Item 9.01 — Financial Statements and Exhibits
Dianthus Therapeutics executed an underwriting agreement for an equity offering including pre-funded warrants on March 10, 2026.
Added in current filing · verify on EDGAR →
Underwriting Agreement, dated as of March 10, 2026, by and among Dianthus Therapeutics, Inc., Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC
The company entered into an underwriting agreement with five investment banks on March 10, 2026. This indicates Dianthus is conducting a public equity offering, which will raise capital but may dilute existing shareholders. The involvement of multiple underwriters suggests a significant financing transaction.
Added in current filing · verify on EDGAR →
Form of Pre-Funded Warrant
The company is issuing pre-funded warrants as part of the offering. Pre-funded warrants are typically sold at a price equal to the stock price minus a nominal exercise price, allowing investors to effectively purchase shares upfront while deferring technical ownership. This structure is often used to accommodate investors with ownership limitations.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify